Literature DB >> 17262714

Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.

Tamara S Flys1, Deborah Donnell, Anthony Mwatha, Clemensia Nakabiito, Philippa Musoke, Francis Mmiro, J Brooks Jackson, Laura A Guay, Susan H Eshleman.   

Abstract

K103N-containing human immunodeficiency virus (HIV)-1 variants are selected in some women who receive single-dose (SD) nevirapine (NVP) for prevention of HIV-1 mother-infant transmission. We examined the persistence of K103N in women who received SD NVP prophylaxis. K103N was detected using the LigAmp assay (assay cutoff, 0.5% K103N). K103N was detected at 6-8 weeks in 60 (41.7%) of 144 women. Fading (lack of detection) of K103N was documented in 16 women by 2 years, 43 women by 3 years, and 55 women by 4 and 5 years. Slower fading was independently associated with HIV-1 subtype (D>A) and higher pre-NVP viral load.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17262714     DOI： 10.1086/511433

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  35 in total

1.  HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.

Authors:  Gillian M Hunt; Ashraf Coovadia; Elaine J Abrams; Gayle Sherman; Tammy Meyers; Lynn Morris; Louise Kuhn
Journal:  AIDS       Date:  2011-07-31       Impact factor: 4.177

2.  Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.

Authors:  Judith N Dlamini; Zonghui Hu; Harsha Somaroo; Helene C Highbarger; Dean A Follmann; Robin L Dewar; Alice K Pau
Journal:  Pharmacotherapy       Date:  2011-02       Impact factor: 4.705

3.  Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.

Authors:  Sherry L Farr; Julie A E Nelson; Thokozani J Ng'ombe; Athena P Kourtis; Charles Chasela; Jeffrey A Johnson; Angela D M Kashuba; Gerald L Tegha; Jeffrey Wiener; Joseph J Eron; Harriet N Banda; Mwanangwa Mpaso; Jonathan Lipscomb; Chrissie Matiki; Susan A Fiscus; Denise J Jamieson; Charles van der Horst
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

4.  Human Immunodeficiency Virus Antiretroviral Resistance and Transmission in Mother-Infant Pairs Enrolled in a Large Perinatal Study.

Authors:  Nava Yeganeh; Tara Kerin; Bonnie Ank; D Heather Watts; Margaret Camarca; Esau C Joao; Jose Henrique Pilotto; Valdilea G Veloso; Yvonne Bryson; Glenda Gray; Gerhard Theron; Ruth Dickover; Mariza G Morgado; Breno Santos; Regis Kreitchmann; Lynne Mofenson; Karin Nielsen-Saines
Journal:  Clin Infect Dis       Date:  2018-05-17       Impact factor: 9.079

5.  Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection.

Authors:  Hans-Jürgen Stellbrink
Journal:  Core Evid       Date:  2010-06-15

6.  Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature.

Authors:  Ennio Polilli; Giustino Parruti; Luana Cosentino; Federica Sozio; Annalisa Saracino; Augusta Consorte; Gioacchino Angarano; Francesco Di Masi; Elena Mazzotta; Paolo Fazii
Journal:  J Med Case Rep       Date:  2009-09-18

7.  Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants.

Authors:  Jessica D Church; Wei Huang; Neil Parkin; Natalia Marlowe; Laura A Guay; Saad B Omer; Philippa Musoke; J Brooks Jackson; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2009-07       Impact factor: 2.205

8.  Analysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq).

Authors:  William Ian Towler; Jessica D Church; James R Eshleman; Mary Glenn Fowler; Laura A Guay; J Brooks Jackson; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

9.  Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda.

Authors:  Susan H Eshleman; Oliver Laeyendecker; Neil Parkin; Wei Huang; Colombe Chappey; Agnes C Paquet; David Serwadda; Steven J Reynolds; Noah Kiwanuka; Thomas C Quinn; Ronald Gray; Maria Wawer
Journal:  AIDS       Date:  2009-04-27       Impact factor: 4.177

10.  Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission.

Authors:  Tamara S Flys; Michelle S McConnell; Flavia Matovu; Jessica D Church; Danstan Bagenda; Leila Khaki; Paul Bakaki; Michael C Thigpen; Chineta Eure; Mary Glenn Fowler; Susan H Eshleman
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.